-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] The annual report disclosure of major companies is in progress
.
As of March 22, the performance reports of more than 100 pharmaceutical companies have been announced, and more than 70% are good news
.
Among them, Zhifei Biology topped the list with a net profit of 10.
197 billion yuan, and Jimin Medical’s net profit increased by 2205.
39%
.
On March 23, three more pharmaceutical companies disclosed their annual performance reports, namely Ma Yinglong, Boya Bio, and Fosun Pharma, and all three companies reported good results
.
Ma Yinglong: Net profit increased by 10.
87% year-on-year.
According to Ma Yinglong's 2021 annual report, the company's operating income from January to December 2021 was 3.
385 billion yuan, a year-on-year increase of 21.
26%.
The net profit attributable to shareholders of the listed company was 465 million yuan, a year-on-year increase of 10.
87% , earnings per share was 1.
0800 yuan
.
The company's main business is pharmaceutical manufacturing, pharmaceutical retail and wholesale, and medical services
.
During the reporting period, the main business income of the pharmaceutical industry, medical services and pharmaceutical business increased by 21.
42%, 33.
77% and 25.
26% respectively year-on-year
.
Among them, the increase in the operating income of the pharmaceutical industry was mainly due to a year-on-year increase of 18.
81% in the operating income of the company's hemorrhoid treatment products; the increase in the operating income of medical services was mainly due to the year-on-year increase in the revenue of the company's directly-operated hospitals and Ma Wanxing; the growth of the pharmaceutical business operating income was mainly due to Businesses such as pharmaceutical retail and wholesale distribution have grown significantly year-on-year, especially the scale of pharmaceutical retail B2C business has grown significantly
.
Boya Bio: Net profit increased by 32.
48% year-on-year In 2021, Boya Bio will realize main income of 2.
651 billion yuan, a year-on-year increase of 5.
47%; net profit attributable to the parent is 345 million yuan, a year-on-year increase of 32.
48%; basic earnings per share are 0.
79 yuan
.
In addition, the company plans to distribute a cash dividend of 1.
50 yuan for every 10 shares
.
The company's main business is the research and development, production and sales of blood products.
The products cover 8 varieties and 22 specifications of products such as human albumin, intravenous human immunoglobulin (pH4) and coagulation factors
.
Fosun Pharma: Net profit increased by 29.
28% year-on-year According to the 2021 annual report disclosed by Fosun Pharma, the company achieved operating income of 39.
005 billion yuan, a year-on-year increase of 28.
7%; net profit attributable to the parent was 4.
735 billion yuan, a year-on-year increase of 29.
28%
.
The business directly operated by the company includes pharmaceuticals, medical devices and medical diagnosis, medical and health services, and covers the pharmaceutical business field through the participation in Sinopharm Holding, of which pharmaceuticals are the core business
.
According to reports, during the reporting period, the group continued to adhere to the business philosophy of "continuous innovation and enjoyment of health", continued to promote innovation and transformation, and comprehensively accelerated its internationalization.
The improvement of the quality and efficiency of the operation of the enterprise has achieved steady growth in performance
.
Regarding the main performance drivers, the company stated that there are two aspects: First, the optimization of product structure brought about by the launch of innovative products is the main driver of performance during the reporting period
.
The Group focuses on diseases and technologies that are oriented by clinical needs, have precise curative effects, and are in line with the development of modern medicine.
Product development and transformation
.
After more than ten years of continuous investment, Hanlikang, Hanquyou, Su Kexin, Fubitai (Hong Kong, Macao and Taiwan markets) and other varieties have been approved and sold in large volumes in the past three years, promoting sustainable growth in performance
.
Second, the integration effect is gradually emerging
.
The Group actively promotes the integration of systems and resources such as research and development, supply chain, production and marketing, in order to enhance synergy and operational efficiency, and promote steady growth in performance
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
As of March 22, the performance reports of more than 100 pharmaceutical companies have been announced, and more than 70% are good news
.
Among them, Zhifei Biology topped the list with a net profit of 10.
197 billion yuan, and Jimin Medical’s net profit increased by 2205.
39%
.
On March 23, three more pharmaceutical companies disclosed their annual performance reports, namely Ma Yinglong, Boya Bio, and Fosun Pharma, and all three companies reported good results
.
Ma Yinglong: Net profit increased by 10.
87% year-on-year.
According to Ma Yinglong's 2021 annual report, the company's operating income from January to December 2021 was 3.
385 billion yuan, a year-on-year increase of 21.
26%.
The net profit attributable to shareholders of the listed company was 465 million yuan, a year-on-year increase of 10.
87% , earnings per share was 1.
0800 yuan
.
The company's main business is pharmaceutical manufacturing, pharmaceutical retail and wholesale, and medical services
.
During the reporting period, the main business income of the pharmaceutical industry, medical services and pharmaceutical business increased by 21.
42%, 33.
77% and 25.
26% respectively year-on-year
.
Among them, the increase in the operating income of the pharmaceutical industry was mainly due to a year-on-year increase of 18.
81% in the operating income of the company's hemorrhoid treatment products; the increase in the operating income of medical services was mainly due to the year-on-year increase in the revenue of the company's directly-operated hospitals and Ma Wanxing; the growth of the pharmaceutical business operating income was mainly due to Businesses such as pharmaceutical retail and wholesale distribution have grown significantly year-on-year, especially the scale of pharmaceutical retail B2C business has grown significantly
.
Boya Bio: Net profit increased by 32.
48% year-on-year In 2021, Boya Bio will realize main income of 2.
651 billion yuan, a year-on-year increase of 5.
47%; net profit attributable to the parent is 345 million yuan, a year-on-year increase of 32.
48%; basic earnings per share are 0.
79 yuan
.
In addition, the company plans to distribute a cash dividend of 1.
50 yuan for every 10 shares
.
The company's main business is the research and development, production and sales of blood products.
The products cover 8 varieties and 22 specifications of products such as human albumin, intravenous human immunoglobulin (pH4) and coagulation factors
.
Fosun Pharma: Net profit increased by 29.
28% year-on-year According to the 2021 annual report disclosed by Fosun Pharma, the company achieved operating income of 39.
005 billion yuan, a year-on-year increase of 28.
7%; net profit attributable to the parent was 4.
735 billion yuan, a year-on-year increase of 29.
28%
.
The business directly operated by the company includes pharmaceuticals, medical devices and medical diagnosis, medical and health services, and covers the pharmaceutical business field through the participation in Sinopharm Holding, of which pharmaceuticals are the core business
.
According to reports, during the reporting period, the group continued to adhere to the business philosophy of "continuous innovation and enjoyment of health", continued to promote innovation and transformation, and comprehensively accelerated its internationalization.
The improvement of the quality and efficiency of the operation of the enterprise has achieved steady growth in performance
.
Regarding the main performance drivers, the company stated that there are two aspects: First, the optimization of product structure brought about by the launch of innovative products is the main driver of performance during the reporting period
.
The Group focuses on diseases and technologies that are oriented by clinical needs, have precise curative effects, and are in line with the development of modern medicine.
Product development and transformation
.
After more than ten years of continuous investment, Hanlikang, Hanquyou, Su Kexin, Fubitai (Hong Kong, Macao and Taiwan markets) and other varieties have been approved and sold in large volumes in the past three years, promoting sustainable growth in performance
.
Second, the integration effect is gradually emerging
.
The Group actively promotes the integration of systems and resources such as research and development, supply chain, production and marketing, in order to enhance synergy and operational efficiency, and promote steady growth in performance
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
